Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
about
Predicting resistance mutations using protein design algorithmsDifferences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacityFitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CPatients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progressionEstimating HIV-1 fitness characteristics from cross-sectional genotype dataThe non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Antiviral drug resistance as an adaptive processHIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitnessThe L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Clinical management of HIV drug resistance.Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.Clinical significance of human immunodeficiency virus type 1 replication fitness.Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacityNucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
P2860
Q27663576-2552166F-1AED-46E8-B963-06D0361DB66BQ28477017-D19EB508-2CE5-4AA1-9E44-47B1FE6D8BE7Q28477614-CE872FB9-DC4C-4061-B8DB-6261F7AC9019Q28484213-B4270EA1-D903-44C1-BD62-F957ACE9EC52Q28542678-5179D556-3A93-4B38-81B8-4BE214DBC5DAQ28544753-C2B81E62-FE0E-46E7-BFDB-9121A91E4C3EQ33872810-F0F8E339-313E-4C8D-8600-9C7E20604581Q33878407-836FF3EF-CBF5-4A26-AF6D-F7177A95DC7AQ33900459-9EE8CE49-DFBD-43E2-83AA-265AAAEBF2B5Q34059119-0CD24C73-21F2-4F2D-A627-42322067BF8DQ34148077-20938798-F1E1-4719-9B6E-45631A37C84DQ34626108-78CF980D-4FB2-451C-93EB-251F6AC055FBQ34681252-78CA7818-C26D-4814-A0E5-82A891BF9B72Q34933329-DD4507E2-F513-4983-A4D4-8131D2E5098EQ35237036-40334D09-FBA4-42C0-82AA-F8B24FFDB701Q35261045-20484636-01E0-4477-B242-D477553704AFQ35363594-66BD079A-E4EF-4AF7-91F2-A97A53E4C021Q35784897-774DD78A-6AF6-4CA3-9239-0BEAFEAC4941Q35959266-7355C0E3-0706-47FF-A11D-0878524EFF70Q36290768-BDD603AB-6F9C-4FBE-9477-D81F9A6E4AA1Q36394656-71A263DE-39FA-4AB6-AE9F-58EC4E085207Q36969857-6595162A-B9E8-43DA-82FC-5F35D4438CEAQ37025712-A28F78D6-5A95-4F1A-8DA4-D01FAB3BDF99Q37072022-3C4C0CE3-A71C-46A9-A037-B5C798B13624Q42211665-D639AEF7-FC28-42E8-917F-E7D4C69269F1Q43146308-11CCD8FC-C1CB-43E1-BCD8-E7165F13AA27Q46499496-4A6FF596-1233-4D2A-A21A-B0A053136B0C
P2860
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@ast
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@en
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@nl
type
label
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@ast
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@en
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@nl
prefLabel
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@ast
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@en
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@nl
P2093
P2860
P356
P1433
P1476
Fitness comparison of thymidin ...... immunodeficiency virus type 1.
@en
P2093
Daniel R Kuritzkes
Françoise Giguel
Hiroyu Hatano
Patrick Reid
P2860
P304
P356
10.1128/JVI.02747-05
P407
P577
2006-07-01T00:00:00Z